CJC-1295 vs ipamorelin: what the evidence compares
Two growth hormone secretagogues that act on different receptors. No study cited here compared them or tested them together. What each one's evidence shows.
Peptio Research
On this page7
No study cited on this page gave both CJC-1295 and ipamorelin, compared one with the other, or tested them together. Each has its own small body of evidence, mostly in healthy volunteers and animals, and neither has a human study measuring muscle, fat, strength, recovery, sleep or ageing. What can be set side by side is how each is built to act, what was measured in people, what went wrong, and what FDA has said about each.
How each is built to act
Both raise growth hormone, through different receptors.
Ipamorelin mimics ghrelin. FDA's 2024 briefing describes it as a synthetic pentapeptide that acts as a ghrelin mimetic and stimulates growth hormone release from the anterior pituitary without major effects on adrenocorticotropic hormone or cortisol levels 1. The experimental evidence for that selectivity comes from swine, in a study by its developer 2; it has not been shown in a published human study cited here.
CJC-1295 mimics growth hormone-releasing hormone (GHRH). The developer's 2005 paper describes it as a modified form of the first 29 amino acids of GHRH, with an added group that binds albumin in the blood 3. FDA calls the version with that group CJC-1295 DAC and the version without it CJC-1295, and describes them as two different active moieties that are not interchangeable 4. Every published human study used the DAC version, by FDA's reading; FDA found no pharmacological study of the version without it 4.
The two are often sold together, and FDA's ipamorelin briefing reports that compounding pharmacy websites offered ipamorelin alone or combined with CJC-1295 1. In that briefing, the CJC-1295 in such combinations is identified as the version without DAC 1, the version FDA found no study of in people 4. So the human evidence below for CJC-1295, all of it on the DAC version, does not describe what those products contain. Acting on different receptors is not evidence that the two do more together than apart, and no study cited here tested them together.
What was measured in people
Apart from one surgical trial of ipamorelin, the human studies of both measured hormone levels, not outcomes.
For ipamorelin, single intravenous infusions in healthy men produced one short pulse of growth hormone that peaked at 0.67 hours, and ipamorelin's terminal half-life was 2 hours 5. Its one published efficacy trial, a small phase 2 trial in hospital patients after bowel surgery, found no significant difference from placebo in recovery of gut function (p = 0.15) 6. A second trial in the same setting enrolled 320 people and has no results posted 7.
For CJC-1295 with DAC, two randomised placebo-controlled trials in healthy adults found that a single injection raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, and the estimated half-life of CJC-1295 itself was 5.8 to 8.1 days 8. By FDA's reading, the rise in growth hormone exposure was significant against placebo only at the three higher doses 4. In healthy men measured before and after one injection, the normal pulses of growth hormone continued while trough levels rose 7.5-fold and IGF-I 45% 9. Its one trial in patients, in HIV-associated visceral obesity, was terminated in 2006 with no reason on the registry and no results 10.
| Ipamorelin | CJC-1295 with DAC | |
|---|---|---|
| Acts on | Ghrelin receptor 1 | GHRH receptor 4 |
| Human studies | Healthy men, single infusions, no control group; one randomised phase 2 efficacy trial in surgical patients 5 6 | Healthy adults, two randomised placebo-controlled trials and one before-and-after study 8 9 |
| Measured | Growth hormone; recovery of gut function after surgery | Growth hormone and IGF-I |
| Clinical result | No significant difference from placebo 6 | No patient trial has reported 10 |
| Muscle, body fat, strength, sleep or ageing | No published human study 5 6 | No published human study 8 9 |
The version of CJC-1295 without DAC is not in the table because FDA found no study of it in people or animals 4.
What went wrong
Each compound's safety record in people comes from a handful of small studies, and FDA read the full papers for both.
For ipamorelin, the trial abstract reports adverse events of any kind in 87.5% on ipamorelin and 94.8% on placebo, and calls it well tolerated 6. FDA, reading the full paper, reports serious adverse events in 17.9% against 15.5%, with no statistical comparison, and that hypokalaemia (12.5% against 3.4%), insomnia (10.7% against 5.2%) and hyperglycaemia at discharge (14.3% against 8.6%) were more frequent than on placebo, and that two people on ipamorelin died after colon cancer surgery complicated by an anastomotic leak; FDA writes that it is unclear whether the deaths were related to ipamorelin 1.
For CJC-1295 with DAC, the trial abstract reports no serious adverse reactions 8. FDA, reading the full papers, reports injection-site reactions in about 70% of healthy volunteers in the first trial, headache in 63% against 14% on placebo in the first trial and 20 to 80% across dose groups against 50% in the second, and flushing, warmth and transient low blood pressure in 30% 4. FDA also describes anecdotal reports of a participant in the patient trial who had a heart attack after an injection and died, and the attending physician's view that the most likely explanation was asymptomatic coronary artery disease with plaque rupture; FDA also states that the developer withdrew CJC-1295 with DAC from clinical trials in 2006 after the death 4. No source establishes whether the drug played a part.
The animal and laboratory records differ. For ipamorelin, FDA found no published repeat-dose toxicity, genotoxicity or carcinogenicity studies at all 1. For CJC-1295 with DAC, FDA describes a genotoxic signal in mouse pituitary cells, injection-site haemorrhage, inflammation and necrosis in rats and dogs given repeated injections, and says pituitary hyperplasia and tumours from long-term use cannot be ruled out 4. An absence of studies is not evidence of safety, so this is not a ranking. FDA raises immunogenicity as a concern for compounded forms of both 11.
Where each stands with regulators
Neither is approved by FDA. Both were nominated for the list of bulk substances that pharmacies may compound with under section 503A, and in 2024 FDA proposed not adding either 1 4. Asked whether each should be placed on the list, its advisory committee voted 0 yes, 12 no and 1 abstaining for each form of ipamorelin 12, and 0 yes and 13 no for four forms of CJC-1295, with 1 yes and 12 no for CJC-1295 acetate 13. Neither appears in any category of FDA's 503A list updated 14 May 2026 14. The documents read for this page do not show a final determination.
FDA's page on compounding safety risks, current as of 22 April 2026, places ipamorelin acetate in Category 2 for outsourcing facilities, substances that raise significant safety risks, and lists both CJC-1295 and ipamorelin acetate among nominations withdrawn by their nominators, noting that ipamorelin acetate remains in 503B Category 2 11. In a joint statement with Australia's Chief Medical Officer of 19 June 2026, the TGA names CJC-1295, though not ipamorelin, among unapproved peptide products it has not evaluated for safety, quality or effectiveness; the statement was read in a browser by a person because the TGA's website could not be reached from the environment used to research this page 15.
What is in a product
Seized products have not always matched their names. Powders seized by Danish customs were identified as analogues of growth hormone secretagogues, including ipamorelin, each with an extra glycine at one end 16. A preparation seized in Norway contained a 29 amino acid peptide consistent with a peptide marketed as CJC-1295 17, and FDA reports that the preparation did not contain DAC: it was the version of which FDA found no human study 4.
Anti-doping
The World Anti-Doping Agency's Prohibited List names both under S2.2.4, growth hormone releasing factors, prohibited at all times: CJC-1295 among growth hormone-releasing hormone analogues, ipamorelin among growth hormone secretagogues. The list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients 18. Earlier second-hand accounts agree. FDA's briefings state that ipamorelin is on WADA's list under section S2.4, citing the 2023 list 1, and, in a footnote citing the list as accessed in April 2024, that growth hormone secretagogues including CJC-1295 are listed as prohibited at all times 4.
The ipamorelin and CJC-1295 pages set out each compound's evidence in full.
Peptides covered
Research areas
Sources
- 1. FDA Briefing Document, Pharmacy Compounding Advisory Committee, October 29, 2024: Ipamorelin-Related Bulk Drug Substances (Ipamorelin (free base) and Ipamorelin Acetate). U.S. Food and Drug Administration. 2024. View source(open access)
- 2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue.. European Journal of Endocrinology. 1998. PubMed 9849822
- 3. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology. 2005. PubMed 15817669
- 4. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: CJC-1295-Related Bulk Drug Substances. U.S. Food and Drug Administration. 2024. View source(open access)
- 5. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharmaceutical Research. 1999. PubMed 10496658
- 6. Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. International Journal of Colorectal Disease. 2014. PubMed 25331030
- 7. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. ClinicalTrials.gov. 2014. NCT01280344(open access)
- 8. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of Clinical Endocrinology & Metabolism. 2006. PubMed 16352683
- 9. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. The Journal of Clinical Endocrinology & Metabolism. 2006. PubMed 17018654
- 10. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov. 2006. NCT00267527(open access)
- 11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 12. Pharmacy Compounding Advisory Committee, October 29, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2024. View source(open access)
- 13. Pharmacy Compounding Advisory Committee, December 4, 2024: Final Summary Minutes. U.S. Food and Drug Administration. 2025. View source(open access)
- 14. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 15. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026. View source(open access)
- 16. Gajda PM et al. Glycine-modified growth hormone secretagogues identified in seized doping material.. Drug Testing and Analysis. 2019. PubMed 30136411
- 17. Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.. Drug Testing and Analysis. 2010. PubMed 21204297
- 18. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026. View source(open access)